Literature DB >> 7499082

Pathology of the iridocorneal-endothelial syndrome. The ICE-cell.

S G Levy1, A C McCartney, M H Baghai, M C Barrett, J Moss.   

Abstract

PURPOSE: The iridocorneal-endothelial (ICE) syndrome is characterized by glaucoma, corneal failure, and iris destruction. Specular photomicroscopy of the corneal endothelium in this disease shows a population of abnormal cells named ICE-cells. Comparison between ultrastructural examination and specular photomicroscopy demonstrates that the histologic equivalent of ICE-cells are cells with an epithelial phenotype. The authors have studied the differentiation markers expressed by ICE-cells using an ultrastructural immunocytochemical technique.
METHODS: Seven keratoplasty specimens from patients with the ICE syndrome were examined by scanning and transmission electron microscopy and light and electron microscopic immunocytochemistry. Comparison was made with three normal corneas. Immunocytochemical studies were performed with monoclonal antibodies to broad-spectrum cytokeratins, cytokeratins 3, 5/8, 8/18 and 19, vimentin, and epithelial membrane antigen.
RESULTS: ICE-cells were morphologically similar to epithelial cells and expressed the same profile of differentiation markers as did normal limbal epithelial cells.
CONCLUSIONS: ICE-cells may arise from an embryologic ectopia of ocular surface epithelium. Alternatively, these findings are consistent with a metaplastic stimulus resulting in a profound change in the phenotype of normal corneal endothelial cells.

Entities:  

Mesh:

Year:  1995        PMID: 7499082

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Confocal microscopy in the iridocorneal endothelial syndrome.

Authors:  A G Chiou; S C Kaufman; R W Beuerman; T Ohta; V Yaylali; H E Kaufman
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

Review 2.  [Glaucoma with primary iris malformations. Axenfeld-Rieger syndromes, ICE syndromes (essential iris atrophy, Chandler's syndrome, Cogan-Reese syndrome), aniridia].

Authors:  K Ninios; C P Jonescu-Cuypers; B Seitz
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

3.  In-vivo confocal microscopy of iridocorneal endothelial syndrome.

Authors:  Qi-Hua Le; Xing-Huai Sun; Jian-Jiang Xu
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

4.  Unique variations and characteristics of iridocorneal endothelial syndrome in China: a case series of 58 patients.

Authors:  Bo Feng; Xin Tang; Hong Chen; Xia Sun; Ningli Wang
Journal:  Int Ophthalmol       Date:  2017-10-10       Impact factor: 2.031

Review 5.  Diseases of the corneal endothelium.

Authors:  Lauren J Jeang; Curtis E Margo; Edgar M Espana
Journal:  Exp Eye Res       Date:  2021-02-14       Impact factor: 3.467

6.  Effect of Stem Cell-Derived Extracellular Vesicles on Damaged Human Corneal Endothelial Cells.

Authors:  Raffaele Nuzzi; Lola Buono; Simona Scalabrin; Marco De Iuliis; Benedetta Bussolati
Journal:  Stem Cells Int       Date:  2021-01-16       Impact factor: 5.443

7.  Extracellular Vesicles Derived From Human Corneal Endothelial Cells Inhibit Proliferation of Human Corneal Endothelial Cells.

Authors:  Mohit Parekh; Hefin Rhys; Tiago Ramos; Stefano Ferrari; Sajjad Ahmad
Journal:  Front Med (Lausanne)       Date:  2022-02-04

Review 8.  Diagnosis and Management of Iridocorneal Endothelial Syndrome.

Authors:  Marta Sacchetti; Flavio Mantelli; Marco Marenco; Ilaria Macchi; Oriella Ambrosio; Paolo Rama
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

9.  Iridocorneal endothelial syndrome in a patient with keratoconus - a case report.

Authors:  Michele De Maria; Danilo Iannetta; Antonio Moramarco; Luigi Fontana
Journal:  BMC Ophthalmol       Date:  2019-11-11       Impact factor: 2.209

10.  Continuous acellular material accumulation in the anterior chamber associated with corneal endothelial changes.

Authors:  Jun Shimazaki; Seika Den; Yoshiyuki Satake; Kazunari Higa
Journal:  BMJ Case Rep       Date:  2020-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.